Abbott Says FDA Approves Spinal Cord Stimulation Devices To Treat Chronic Back Pain
(RTTNews) - Abbott Laboratories (ABT) announced Tuesday that the U.S. Food and Drug Administration (FDA) has approved its spinal cord stimulation (SCS) devices for the treatment of chronic back pain in people who have not had or are not eligible to receive back surgery, known as non-surgical back pain.
This labeling expansion was supported by results from the DISTINCT study, which demonstrated that Abbott's proprietary BurstDR SCS technology improved pain levels, ability to perform daily activities and emotional well-being in people with chronic back pain.
Abbott's DISTINCT study, which enrolled 270 participants who suffered for an average of 12.8 years with pain, is the largest randomized controlled trial for SCS in people with chronic back pain when surgery is not an option.
Results at six months for the first 200 patients demonstrated clear clinical evidence supporting BurstDR stimulation therapy as an effective treatment for chronic back pain and were sustained at the 12-month follow-up.
This new indication will span across the entirety of Abbott's SCS portfolio in the U.S., which includes the recharge-free Proclaim SCS family and the rechargeable Eterna SCS platform. All of Abbott's SCS therapies in the U.S. feature the company's proprietary, low-energy BurstDR waveform.
Abbott Laboratories Boosts FY24 Earnings Outlook - Update
Abbott Says FDA Approves First-of-Its-Kind TriClip Transcatheter Edge-to-edge Repair System
Abbott Laboratories Guides FY24 Adj. EPS In Line With Estimates - Update
Abbott Inks Deal With MAbxience To Commercialize Biosimilar Molecules In Emerging Markets
Abbott Laboratories Reaffirms FY23 Adj. EPS Outlook - Update
Abbott Laboratories Says FDA Approves Assert-IQ Insertable Cardiac Monitor
Abbott Announces Two New FDA Clearances For Life Support System
